Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Board declares interim dividend of Rs 2 per equity share
This work has been published in the journal ‘ACS applied materials and interface’
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Board approves fundraise of Rs 1500 crore
Forex gains stood at Rs 20 crore for the quarter
The company expects revenue growth of 10-15 per cent in the US
Subscribe To Our Newsletter & Stay Updated
